<DOC>
	<DOCNO>NCT01599754</DOCNO>
	<brief_summary>The purpose trial determine adjuvant therapy axitinib prevent delay recurrence renal cell cancer surgery remove primary tumor high risk patient .</brief_summary>
	<brief_title>Adjuvant Axitinib Therapy Renal Cell Cancer High Risk Patients</brief_title>
	<detailed_description>This prospective , randomize , double blind placebo control Phase 3 trial oral axitinib start 5 mg twice daily give 3 year vs. placebo . Approximately 700 patient randomize 1:1 ratio axitinib v placebo .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients must treat nephrectomy patient must meet follow inclusion criterion eligible enrollment trial : 1 . Patients must evidence macroscopic residual disease metastatic disease . 2 . Male female , age &gt; =18 year ( age &gt; =20 year Japan , Korea Taiwan ) . 3 . Patients must diagnose one follow base American Joint Committee Cancer ( AJCC ) TNM stag version 2010 , Eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) : pT2 , pN0 pNx , M0 ECOG PS 01 pT3 , pN0 pNx , M0 ECOG PS 01 pT4 , pN0 pNx , M0 ECOG PS 01 Any pT , pN1 , M0 ECOG PS 01 4 . Patients must histologically confirm preponderant , define &gt; 50 % , clear cell RCC . 5 . Patients must receive previous systemic ( include chemotherapeutic , hormonal , immunotherapeutic ) treatment RCC . 6 . Patients must receive previous anti angiogenic treatment . 7 . Patients must adequate organ function . Exclusion Criteria 1 . Histologically undifferentiated carcinoma , sarcoma , collect duct carcinoma , lymphoma , patient metastatic renal site . 2 . National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade 3 hemorrhage &lt; 4 week date randomization . 3 . Diagnosis nonRCC malignancy within 5 year date randomization , except basal cell carcinoma , squamous cell skin cancer , situ carcinoma cervix uteri adequately treat evidence recurrent disease 12 month . 4 . Any follow within 12 month prior study drug administration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack 6 month deep vein thrombosis pulmonary embolism . 5 . Gastrointestinal abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>axitinib</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>